Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Iqvia has led a $15m series C round for MIT-founded genomic data analytics spinout BC Platforms as part of a strategic partnership agreement.

EPFL's cancer drug developer Cellestia Biotech has extended its funding haul to $48.6m in a series B round that featured existing investor PPF Group.

Managing director Evan Norton has stepped down from Abbott Ventures after leading the unit’s investment initiatives for nearly a decade, moving to Accelmed.

MIT-founded genomic data analytics spinout BC Platforms raised the cash in a series C round led by newly minted strategic partner Iqvia.

Medipal and Sony Innovation Fund by IGV were among the investors that boosted the liver disease drug developer's latest round to $52.6m.

Lenskart will exit the vision-testing app developer in an acquisition expected to be around the $100m mark, two years after investing $1m.

Genetic disease drug developer Triplet Therapeutics has emerged from stealth with $59m including $49m in a round co-led by Pfizer Ventures.

Guangxi Royal Dairy committed nearly half the capital for the venture firm's latest fund, which has closed at $86.7m.

CU Boulder spinout Inscripta has now accumulated more than $259m from investors including Institut Mérieux, and will use the capital to further expand its genome engineering platform.